{"organizations": [], "uuid": "4715a7dd929ea98200d9a81eb2170b117ea03408", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-aratana-therapeutics-expands-thera/brief-aratana-therapeutics-expands-therapeutic-candidate-pipeline-idUSFWN1QJ0OX", "country": "US", "domain_rank": 408, "title": "BRIEF-Aratana Therapeutics Expands Therapeutic Candidate Pipeline", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-01T15:48:00.000+02:00", "replies_count": 0, "uuid": "4715a7dd929ea98200d9a81eb2170b117ea03408"}, "author": "", "url": "https://www.reuters.com/article/brief-aratana-therapeutics-expands-thera/brief-aratana-therapeutics-expands-therapeutic-candidate-pipeline-idUSFWN1QJ0OX", "ord_in_thread": 0, "title": "BRIEF-Aratana Therapeutics Expands Therapeutic Candidate Pipeline", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "aratana therapeutics inc", "sentiment": "none"}, {"name": "pipeline reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 1, 2018 / 1:48 PM / Updated 11 minutes ago BRIEF-Aratana Therapeutics Expands Therapeutic Candidate Pipeline Reuters Staff March 1 (Reuters) - Aratana Therapeutics Inc: * ARATANA THERAPEUTICS EXPANDS THERAPEUTIC CANDIDATE PIPELINE * ARATANA THERAPEUTICS INC - ANNOUNCED AN ANIMAL HEALTH RESEARCH AND DEVELOPMENT COLLABORATION WITH ASKAT INC * ARATANA THERAPEUTICS INC - LICENSED EXCLUSIVE, WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE AT-019, KNOWN AS AAT-008 BY ASKAT * ARATANA THERAPEUTICS INC - AT-019 LICENSE AGREEMENT INCLUDES AN UPFRONT PAYMENT OF $0.5 MILLION; MILESTONE PAYMENTS OF UP TO $15.5 MILLION Source text for Eikon:  ", "external_links": [], "published": "2018-03-01T15:48:00.000+02:00", "crawled": "2018-03-01T16:01:08.012+02:00", "highlightTitle": ""}